Director/PDMR Shareholding

12 March 2019 12:00 GMT

TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

AstraZeneca PLC (the Company) announces that, on 8 March 2019, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.

PDMR Ordinary Shares granted under the AZDBP Ordinary Shares granted under the AZPSP Award price per Ordinary Share
Pascal Soriot 9,849 102,475 £62.87
Marc Dunoyer 4,874 48,690 £62.87

The AZDBP award represents the portion of each PDMR's annual bonus for 2018 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.

The AZPSP award is subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year performance period (1 January 2019 to 31 December 2021). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.

Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2018, which is available on the Company's website at www.astrazeneca.com/annualreport2018.

1  Details of the person discharging managerial responsibilities / person closely associated 
a)  Name  Pascal Soriot
2  Reason for the notification 
a)  Position/status    Chief Executive Officer
b)   Initial notification /Amendment  Initial notification
3  Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)  Name  AstraZeneca PLC
b)   LEI  PY6ZZQWO2IZFZC3IOL08
4  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)  Description of the financial instrument, type of instrument   Identification code Ordinary Shares of US$0.25 each in AstraZeneca PLC     GB0009895292   
b)   Nature of the transaction  Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan
c)  Price(s) and volume(s)  Price(s) Volume(s) £62.87 112,324
d)  Aggregated information   - Aggregated volume     - Price    Not applicable - single transaction     
e)  Date of the transaction  8 March 2019
f)  Place of the transaction  Outside a trading venue

  

1  Details of the person discharging managerial responsibilities / person closely associated 
a)  Name  Marc Dunoyer
2  Reason for the notification 
a)  Position/status    Chief Financial Officer
b)   Initial notification /Amendment  Initial notification
3  Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)  Name  AstraZeneca PLC
b)   LEI  PY6ZZQWO2IZFZC3IOL08
4  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)  Description of the financial instrument, type of instrument   Identification code Ordinary Shares of US$0.25 each in AstraZeneca PLC     GB0009895292   
b)   Nature of the transaction  Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan
c)  Price(s) and volume(s)  Price(s) Volume(s) £62.87 53,564
d)  Aggregated information   - Aggregated volume     - Price    Not applicable - single transaction     
e)  Date of the transaction  8 March 2019
f)  Place of the transaction  Outside a trading venue

  

  

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Gonzalo Viña UK/Global +44 203 749 5916
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Jennifer Hursit UK/Global +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharma - Cardiovascular; Metabolism +44 203 749 5711
Nick Stone BioPharma - Respiratory; Renal +44 203 749 5716
Josie Afolabi Other +44 203 749 5631
Craig Marks Finance; Fixed Income +44 7881 615 764
Jennifer Kretzmann Retail Investors; Corporate Access +44 203 749 5824
US toll-free +1 866 381 72 77

  

Adrian Kemp 

Company Secretary 

AstraZeneca PLC 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links